Sai Parenteral's Ltd.
NSE & BSE₹372–392
₹ 295 Cr
38 Shares
₹ 14,136
₹5
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 3,809.98 | 1,631.06 | |
| 99.35 | 6.38 | |
| 3,909.33 | 1,637.44 | |
| 3,436.48 | 1,237.21 | |
| 119.28 | 199.09 | |
| 142.59 | 144.27 |
Subscription Details
Subscription
IPO Timeline
IPO Offer Start
24 Mar 2026
IPO Offer Ends
27 Mar 2026
2 Apr 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Capacity expansion and upgradation of manufacturing facilities | 1,107.95 |
| 2 | Establishment of a new R&D Centre | 180.23 |
| 3 | Repayment / prepayment of certain outstanding borrowings | 143.02 |
| 4 | Working capital requirements | 330 |
| 5 | Investment in wholly owned subsidiary, Sai Parenterals Pte Limited | 356.41 |
| 6 | General corporate purposes | 447.4 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
61.23%
Promoter stake
Post-IPO
51.16%
Promoter stake
Offered to Public
75,22,486
shares
Post Share Capital
2,26,00,001
shares
IPO Registrar
Bigshare Services Pvt Ltd
About the Company
Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Our Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems that include dry powder injections, pre-filled syringes, ampoules, and vials. We manufacture and sell Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. We started our export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. We export our products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors. Our Company’s CDMO business includes comprehensive solutions on product development, validation batches, stability studies, dossier compilation, international regulatory filings and commercial manufacturing. We believe that our R&D expertise and regulatory compliance capabilities positions us as a preferred CDMO partner for our customers in the Regulated and Semi-Regulated Markets. Our Company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte. Limited, has entered into a Share Purchase Agreement dated September 23, 2025 with Noumed Life Sciences Limited (UK), Mark Thulborne, and Jo-maree Delac to acquire a 74.60% majority and controlling stake in Noumed, including an equity infusion of AUD 4.00 million as a primary in Noumed Pharmaceuticals Pte Ltd, Australia. Noumed Pharmaceuticals Pty Limited (“Noumed”), an Australia-based pharmaceutical company in the business of Intellectual Property (IP) dossier-led commercialisation, integrated supply chain management with long-standing partnerships with retail pharmacy networks in Australia. For further details, please see “Objects of the Offer – Investment in wholly owned subsidiary, Sai Parenterals Pte Limited
Use of Proceeds
1. Capacity expansion and upgradation of manufacturing facilities; 2. Establishment of a new R&D Centre; 3. Repayment / prepayment of certain outstanding borrowings; 4. Working capital requirements; 5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and 6. General corporate purposes
Sai Parenteral's Ltd. Latest News
News
Sai Parenterals acquires 60% stake in Prathyak Laboratories for Rs 15 crore
The acquisition was funded from the unutilised net proceeds of the company's initial public offering
Sai Parenterals informs about press release
Sai Parenterals’ arm renews long-term OTC medicines supply contract
The renewed agreement is for a 3-year term with a projected value of around Rs 204 crore
Sai Parenterals submits newspaper advertisement
Sai Parenterals informs about outcome of board meeting
Sai Parenterals surges as its arm renews supply pact with Australian pharmacy network
The renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks
Sai Parenterals' arm renews OTC medicines supply agreement with Australian pharmacy network
The renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks
Sai Parenterals secures 10-year supply order worth Rs 104.50 crore
The order involves supply of anti TB products for Philippines market
Sai Parenteral's coming with IPO to raise upto Rs 424.11 crore
The issue will open for subscription on March 24, 2026 and will close on March 27, 2026
IPO FAQs
The Sai Parenteral's Ltd. IPO has a total of ₹295 crore, calculated at the upper end of the .
The Sai Parenteral's Ltd. IPO is priced at ₹372–392 per share. bids must fall within this , against a of ₹5 per share.
The for the Sai Parenteral's Ltd. IPO is 38 shares, which is also the minimum order quantity — you have to apply for at least 38 shares, and in multiples of 38 beyond that.
The minimum investment in the Sai Parenteral's Ltd. IPO is about ₹14,136 — one lot of 38 shares, calculated at the lower end of the .
Bidding at the cut-off or upper price raises the amount blocked in your account.
The Sai Parenteral's Ltd. opens on 24 Mar 2026 and closes on 27 Mar 2026.
Applications have to be in before 5:00 PM IST on the closing day, and your UPI mandate needs to be approved by then as well.
Sai Parenteral's Ltd. shares were listed on 2 Apr 2026 on BSE and NSE.
Bigshare Services Pvt Ltd is the for the Sai Parenteral's Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them.
Sai Parenteral's Ltd. IPO shares are listed on BSE and NSE.
Each Sai Parenteral's Ltd. share has a of ₹5.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 61.23% of Sai Parenteral's Ltd. before the IPO, which falls to 51.16% after the issue.
75,22,486 shares of Sai Parenteral's Ltd. are being offered to the public in this issue.
The Sai Parenteral's Ltd. IPO has been subscribed 1.05x overall — 1.71x, 2.36x and 0.12x.
figures update through the issue period until it closes.
1. Capacity expansion and upgradation of manufacturing facilities 2. Establishment of a new R&D Centre 3. Repayment / prepayment of certain outstanding borrowings 4. Working capital requirements 5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) 6. General corporate purposes
Arihant Capital Markets Ltd. is the book running lead manager for the Sai Parenteral's Ltd. IPO.
Pre-apply means placing your Sai Parenteral's Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Sai Parenteral's Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Sai Parenteral's Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.